Heath E, et al. - Given that in a preliminary phase I trial adding cediranib (an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptor signaling) to docetaxel plus prednisone (DP) in patients with metastatic castrate-resistant prostate cancer (mCRPC) showed the safety and feasibility of this regimen along with early evidence for effectiveness, researchers performed this multicenter phase 2 trial to evaluate if DP effectiveness was improved when it is used with cediranib in patients with mCRPC. In a random manner, either docetaxel (75 mg/m²intravenously every 3 weeks) with prednisone (5 mg twice daily) plus cediranib (30 mg once daily; the DP+C arm) or DP only (the DP arm) was given to chemotherapy-naive patients with mCRPC. Cediranib in combination with docetaxel + prednisone did not result in superior effectiveness vs docetaxel + prednisone; it also and added toxicity. Based on these findings, pursuing the combination further in patients with mCRPC is not supported.